Additional germline variants influencing drug response have been identified in CRC, such as rs199958833, which may affect 5‐FU sensitivity by destabilizing the cyclin‐dependent kinase 1 (CDK1) protein structure [201]. Here, CDK1 is linked to colorectal carcinoma.